Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O5ER
|
|||
| Former ID |
DNAP001292
|
|||
| Drug Name |
Catumaxomab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Malignant pleural effusion [ICD-11: 2D72; ICD-10: C78.2; ICD-9: 511.81] | Approved | [1], [2] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [3] | ||
| Company |
Fresenius Biotech
|
|||
| SuperDrug ATC ID |
L01XC09
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7385). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | ClinicalTrials.gov (NCT00377429) Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.